

(PF1956) DISCOVERY OF A FIRST-IN-CLASS ALLELE-SELECTIVE XNAZYME THAT KNOCKS DOWN MUTANT JAK2 V617F MRNA IN A MOUSE MODEL OF POLYCYTHEMIA VERA

Topic: 15. Myeloproliferative neoplasms - Biology & translational research

Vadim Fedjuk^{*1}, Alex Rosenberg¹, Einat Amit Romach¹, Rotem Volkman¹, Dmitry Torchinsky¹, Gur Roshwalb¹, Joel Kaye¹

¹ *IE Therapeutics, R&D, Rehovot, Israel;*

Background

Polycythemia vera (PV) is a clonal myeloproliferative neoplasm driven by the somatic JAK2 V617F mutation in 95% of patients. This results in dysregulated erythroid progenitor proliferation and subsequent erythrocytosis with increased blood viscosity and thrombotic risk. Current JAK2 inhibitors lack selectivity for the V617F mutant allele, thereby interfering with WT JAK2-dependent hematopoiesis and leading to cytopenias. In contrast, allele specific knockdown of JAK2 V617F has the potential to be disease-modifying by preferentially suppressing the mutant clone and reducing variant allele burden while sparing WT JAK2 dependent hematopoiesis.

Therapeutic oligonucleotide modalities such as siRNAs and antisense oligonucleotides are powerful tools for targeting the fundamental genetic drivers of disease on the RNA level, providing opportunity to modify disease at its root, however achieving single nucleotide precision with existing technologies remains extremely challenging.

Here, we present 'X-Zymes', chemically evolved catalytic xeno-nucleotide enzymes (XNAzymes) engineered to enable potent, durable and single base allele-selective RNA silencing in vivo.

Aims

To evaluate the allele selectivity and target engagement of X-Zyme targeting mutant JAK2 V617F in preclinical models of PV.

Methods

Fully modified X-Zymes were designed to selectively cleave JAK2 V617F transcripts while sparing wild-type JAK2. Potency and selectivity were assessed using kinetic cleavage assays and allele-specific knockdown in cellular reporter systems. For in vivo proof of concept, the candidate X-Zymes were formulated with NOV340 liposomes and evaluated in a bone marrow transplantation model of PV (SclCre;JAK2-V617F;GFP). Mice were treated with a single IV dose and target engagement was assessed by RT-qPCR quantification of mutant-selective JAK2 V617F knockdown in sorted erythroid progenitors (BFU-E and CFU-E).

Results

X-Zymes demonstrated potent, allele-selective catalytic cleavage of JAK2 V617F with discrimination against wild-type JAK2 and achieved mutant-selective knockdown in cellular assays. NOV340 encapsulation enabled efficient, dose-dependent delivery of the X-Zyme payload to erythroid populations in both bone marrow and spleen. In the PV mouse model, X-Zyme administration resulted in selective knockdown of the V617F mutant allele, and reduction in the frequency of erythroid progenitor cells (CFU-E/BFU-E).

Summary/Conclusion

X-Zymes enable allele-selective degradation of the mutant JAK2 V617F transcript, a mechanistically distinct approach from JAK inhibitors. X-Zymes were delivered to erythroid progenitors and demonstrated median knockdown of mutant JAK2 V617F mRNA by 70%. These data support a potentially disease-modifying strategy for V617F-driven myeloproliferative neoplasms.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. **Abstract Book Citations:** Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.